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ABSTRACT: Background: Neuroinflammation plays a
key role in PD pathogenesis, and allogeneic bone
marrow–derived mesenchymal stem cells can be used as
an immunomodulatory therapy.
Objective: The objective of this study was to prove the
safety and tolerability of intravenous allogeneic bone
marrow–derived mesenchymal stem cells in PD patients.
Methods: This was a 12-month single-center open-
label dose-escalation phase 1 study of 20 subjects with
mild/moderate PD assigned to a single intravenous
infusion of 1 of 4 doses: 1, 3, 6, or 10 × 106 allogeneic
bone marrow–derived mesenchymal stem cells/kg, eval-
uated 3, 12, 24, and 52 weeks postinfusion. Primary
outcome safety measures included transfusion reaction,
study-related adverse events, and immunogenic
responses. Secondary outcomes included impact on
peripheral markers, PD progression, and changes in
brain perfusion.
Results: There were no serious adverse reactions related
to the infusion and no responses to donor-specific
human leukocyte antigens. Most common treatment-
emergent adverse events were dyskinesias (20%, n = 4)
with 1 emergent and 3 exacerbations; and hypertension
(20%, n = 4) with 3 transient episodes and 1 requiring
medical intervention. One possibly related serious
adverse event occurred in a patient with a 4-year history
of lymphocytosis who developed asymptomatic chronic
lymphocytic leukemia. Peripheral inflammation markers
appear to be reduced at 52 weeks in the highest dose
including, tumor necrosis factor-α (P < 0.05), chemokine
(C-C motif ) ligand 22 (P < 0.05), whereas brain-derived
neurotrophic factor (P < 0.05) increased. The highest
dose seems to have demonstrated the most significant
effect at 52 weeks, reducing the OFF state UPDRS
motor, −14.4 (P < 0.01), and total, −20.8 (P < 0.05),
scores.
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Conclusion: A single intravenous infusion of allogeneic
bone marrow–derived mesenchymal stem cells at doses of
1, 3, 6, or 10 × 106 allogeneic bone marrow–derived mesen-
chymal stem cells/kg is safe, well tolerated, and not immu-
nogenic in mild/moderate PD patients. © 2021 The Authors.
Movement Disorders published by Wiley Periodicals LLC on
behalf of International Parkinson and Movement Disorder
Society
Key Words: donor-specific antibodies; neu-
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Neurological disorders are the leading cause of disabil-
ity worldwide, and Parkinson’s disease (PD) is the fastest
growing. Neurodegeneration in PD is relentlessly progres-
sive, creating a compelling need to find effective and safe
disease-modifying therapies. Considerable evidence sup-
ports the critical role of neuroinflammation in the degen-
erative process,1 which is known to be orchestrated by
interactions of glial cells, peripheral lymphocytes,
proinflammatory cytokines/chemokines, and changes in
growth factors.2-5 The inflammatory condition of the
parkinsonian neuronal-glial microenvironment is well
described in human postmortem tissue, in vivo models
(1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine, 6-hydro-
xydopamine, rotenone, lipopolysaccharide (LPS), and
SNc extracts), and in vitro models. Inflammation also
plays a significant role in toxin-induced and genetic
models,6,7 and epidemiological studies on the risk-
lowering effects of anti-inflammatory drug regimens
confirm its vital role.8,9 Our group has studied the
peripheral immune system in PD neurodegeneration by
using LPS rat models,10,11 glial cells,12,13 and patient
cerebrospinal fluid and blood.14,15 Results from these
investigations indicate that an adaptive immune
response contributes to progression and supports the
rationale for using an immune-modulatory therapy such
as mesenchymal stem cells (MSCs). MSCs have been
studied in multiple PD animal models,16-18 and the
potential benefit relies primarily on paracrine actions,
exosomal activity, and modulation of host immune cells.
Preclinical data on MSC therapy has indicated a positive
effect as measured by decreased dopamine (DA) neuron
loss, inflammatory cytokine production, microglial acti-
vation, and α-synuclein oligomerization along with
increased DA neuronal regeneration.19-21
The primary objective of this study was to prove
safety and feasibility in the first-of-its-kind use of allo-
geneic bone marrow–derived mesenchymal stem cells
(allo-hMSCs) delivered intravenously in escalating
doses to patients with idiopathic PD.
Methods
Experimental Design
We conducted a single-center, open-label, ascending-
dose-escalation phase 1 clinical study in patients with
mild to moderate PD. Twenty participants were
enrolled sequentially into 1 of 4 dose groups and
received a single intravenous infusion: group A, 1 × 106
allo-hMSCs/kg; group B, 3 × 106 allo-hMSCs/kg;
group C, 6 × 106 allo-hMSCs/kg; and group D,
10 × 106 allo-hMSCs/kg. Subjects returned for assess-
ments in weeks 3, 12, 24, and 52 after infusion. An
Investigational New Drug (IND) was obtained from the
US Food and Drug Administration (FDA; #16756). A
staggered design was created to maximize safety, which
consisted of a 1 + 1 + 1 + 2 schedule for groups A and
B, followed by a 2 + 3 for groups C and D, with
30 days between infusions. Doses were based on safety
and efficacy literature in various disorders22-28 and the
optimal volume necessary to preserve cell quality and
viability. The sample size of 20 active participants was
based on epidemiological estimates; incidence rates of
potential serious adverse events (SAEs) ranged from
5.5/1,000,000 to 14/1000. The design provided 90%
confidence intervals for detecting a potential SAE that
ranged from 0.2% to 18.3%. The protocol was
approved by our institutional review board (UTHealth
institutional review board), HSC-MS-16-0026, and reg-
istered with clinicaltrials.gov, NCT:02611167. All par-
ticipants provided written informed consent. The study
was conducted according to the International Council
for Harmonization Good Clinical Practice guidelines
and the principles of the Declaration of Helsinki. An
independent data and safety monitoring board (DSMB)
monitored the conduct of the trial and subject safety.
Study Participants
Immunocompetent male and female patients between
45 and 78 years old with mild to moderate PD were
recruited after being screened through a questionnaire
that included medical history details. Critical enroll-
ment criteria included UK Brain Bank criteria; an OFF-
state Hoehn and Yahr scale (H&Y) score ≤ 3; robust
response to dopaminergic therapy, defined as ≥33%
reduction of the Unified Parkinson’s Disease Rating
Scale (UPDRS) motor score in the OFF versus ON
state; a stable dose of dopaminergic replacement at
baseline (≥60 days); and onset of motor symptoms of
≥4 and ≤10 years. Subjects were excluded if they had
features of atypical or secondary parkinsonism; a his-
tory of DBS or ablative brain surgery; or a Montreal
Cognitive Assessment (MoCA) < 23.
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Outcomes
The primary study objective was to evaluate the safety
and tolerability of an intravenous infusion of bone
marrow–derived allo-hMSCs. Exploratory secondary
objectives involved assessing relevant biomarkers for
mechanism of action and clinical assessments of PD
progression.
Safety and tolerability were evaluated by the presence
of treatment-emergent adverse events (TEAEs), labora-
tory tests (complete blood count, complete metabolic
panel, glomerular filtration rate, international normal-
ized ratio, prothrombin time, and partial thromboplas-
tin time), suicidal ideation, physical and neurological
examinations, and changes in panel reactive antibody
(PRA). Exploratory clinical assessments involved 4 dif-
ferent domains (cognition and behavioral changes,
motor function, disability) and quality of life and
included the UPDRS/MDS-UPDRS; H&Y; Timed-Up-
and-Go (TUG); Modified Schwab and England Activi-
ties of Daily Living Scale (ADL); 39-item Parkinson’s
Disease Questionnaire (PDQ-39); MoCA; the Columbia
Suicide Severity Rating Scale; and the 40-item Univer-
sity of Pennsylvania Smell Identification Test (UPSIT).
All the motor assessments were done by a movement
disorders specialist in the conventional OFF state,
defined as being OFF PD medicines 12 hours prior to
the examination. Patients were required to maintain
their baseline dopaminergic regimen for 24 weeks
postinfusion.
Allogeneic Human Mesenchymal Stem Cells
Bone marrow extraction from a healthy donor was
obtained by aspiration under local anesthesia. Testing
was performed using FDA-approved licensed kits by
Gulf Coast Regional Blood Center. MSCs were
expanded using a Terumo Quantum Bioreactor29 by
the Center for Cell and Gene Therapy of Baylor College
of Medicine under current Good Manufacturing
Practices designated by the FDA. The total quantity of
allo-hMSCs was reached in 3 passages. Thawing was ini-
tiated on infusion day, and allo-hMSCs were aliquoted
into a 250-mL transfer pack with 5% buminate. Release
tests were performed on the pooled cells (purity, viability,
cell dose, and microbiological testing).
Peripheral Markers
Serum samples obtained at baseline and after 3, 12,
24, and 52 weeks were analyzed for chemokines, cyto-
kines, and growth factor concentrations using a Mil-
lipore Milliplex MAP 37-plex human cytokine/
chemokine panel and a Milliplex MAP Human Neuro-
degenerative Disease Magnetic Bead Panel 3 (Millipore,
Billerica, MA). Precisely, tumor necrosis factor
(TNF)–α, CXCL10/IP-10, chemokine (C-C motif)
ligand (CCL) 2/monocyte chemoattractant protein-1,
CCL11/Eotaxin, CCL22/MDC, and brain-derived neu-
rotrophic factor (BDNF) were measured. Plates were
analyzed on a Luminex 200 equipped with xPONENT
3.1 software (Luminex, Austin, TX).
Neuroimaging
Participants underwent MRI scanning in the OFF state
at baseline and 24 weeks postinfusion on a 3-Tesla
Philips Ingenia using a 32-channel head coil. Imaging ses-
sions included a high-resolution T1-weighted anatomical
(repetition time/echo time [TR/TE], 8.1/3.7 milliseconds;
flip angle, 6 degrees; matrix size, 256 × 256; field of
view, 256 mm; slice thickness, 1.0 mm, sagittal acquisi-
tion) and a pseudo-continuous arterial spin labeling
(pCASL) sequence (TR/TE, 4550/15.8 milliseconds; flip
angle, 90 degrees; slice thickness, 5 mm; 240-mm field of
view; slice gap, 10 mm; voxel resolution, 1.875 ×
1.875 × 6 mm3; 30 dynamic signal averages, with a
labeling duration of 1650 milliseconds and a postlabeling
delay of 1600 milliseconds) used to measure noncontrast
brain perfusion. Average perfusion in 8 basal ganglia
regions of 2 hemispheres was compared using the multi-
contrast PD25 atlas.30 The PD25 T1 volume with 1-mm
resolution was coregistered to each subject’s native-space
skull-stripped T1 anatomical volume in AFNI.31
Panel Reactive Antibody
Human leukocyte antigen (HLA) level against class I
and class I antigens was assessed using One Lambda
(West Hills, CA) LABScreen Single Antigen Bead Assay
evaluated on either a Luminex 200 or Luminex
LabScan 3D. This information was compared against a
national database to determine the PRA as well as
being interrogated against donor HLA typing to deter-
mine the presence of donor-specific antibodies (DSA).
PRA is based on antibody frequency (not strength) and
is used to determine the percent of the population the
patient will be positive against.
Statistical Analysis
Demographic characteristics and safety data were
summarized using descriptive statistics. Peripheral
markers and rating scales were analyzed per dose
group by 1-way, repeated-measures analysis of vari-
ance (ANOVA) evaluating the effect of time on each
peripheral marker and outcome scale. Statistically reli-
able omnibus (F tests) finds resulted in post hoc
follow-up tests using dependent-sample t tests to eval-
uate each time against its respective baseline. Given
the small sample size, the early phase of investigation
and desire to avoid a potential type II error, we
treated such comparisons as hypothesis-generating
using P ≤ 0.05 as a threshold for statistical testing.
The pCASL regions of interest values were analyzed
using a 3-way ANOVA (region × time × cohort) with
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a Tukey multiple-comparisons correction. An additional
voxel-wise analysis was performed in ExploreASL32 to
examine the location of perfusion changes within the
basal ganglia regions. All analyses were done using
Prism 5.0 (Graph Pad Software, Inc., San Diego, CA).
Results
Study Population
The study prescreened 152 candidates and screened
21. One patient was a screen failure because of renal
insufficiency, and the remaining 20 were sequentially
enrolled in 1 of 4 groups 1, 3, 6, or 10 × 106 allo-
hMSCs/kg of body weight, with n = 5 per group. Base-
line characteristics appeared similar across groups
except for cognition (Table 1). MoCA scores were sig-
nificantly different because of the low mean for group
C (P < 0.05). Subjects had a mean age of 66 years,
H&Y of 2 or 2.5 (65%), disease duration between
4 and 6 years (65%), and mean total UPDRS score of
50.4. All but 1 participant used dopaminergic medica-
tions before baseline evaluation.
Primary Outcome: Safety
All 20 subjects received a single intravenous infusion
and were monitored for 24 hours postinfusion. Three
patients reported TEAEs, 1 phlebitis, 1 antecubital
fossa hematoma, and 1 headache (Table 2). The first
patient had 3 cm superficial phlebitis grade 2 infusion-
related allergic reactions (National Cancer Institute-
Common Terminology Criteria for Adverse Events
(NCI-CTCAE) criteria) that required local medical
management. The other 2 patients had mild symptoms
and did not require any treatment. All patients left the
UTHealth research unit with full resolution of their
symptoms. In subsequent follow-up, 50% of the patients
reported TEAEs; most of them were mild and transient,
with dyskinesia (20%, n = 4) and hypertension (20%,
n = 4) as the most common. Three of the patients experi-
enced exacerbated dyskinetic activity (preexisting dyski-
nesias documented at baseline), 1 at 3 weeks and the
other 2 at 24 weeks postinfusion, requiring levodopa
reduction for resolution; the remaining newly emergent
dyskinesia case presented at 24 weeks and resolved with-
out intervention. Three of the four hypertension cases
were reported between 3 and 12 weeks after infusion and
were followed by their primary care physicians, deter-
mined to be transient and required no intervention. One
patient was diagnosed with stage 2 hypertension that
emerged 24 weeks postinfusion and persisted through the
52-week follow-up period necessitating medical
management.
There was 1 SAE during the study. Eight months
after allo-hMSC infusion, 1 patient in group B, with a
4-year history of lymphocytosis, was diagnosed with
asymptomatic chronic lymphocytic leukemia (CLL).
At the time of enrollment, the patient did not disclose
a previous history of lymphocytosis, was asymptom-
atic, and had a slight increase in lymphocyte percent-
age. The patient’s lymphocyte percentage remained
out of range during the entire study, with normal
white blood cell and lymphocyte absolute numbers.
Based on the lack of literature on this adverse event in
studies with allo-hMSCs, our DSMB decided to label
the SAE as possibly related. At the end of the study,
TABLE 1. Demographics and baseline characteristics
Group A B C D
Dose of MSC/kg 1 × 106 3 × 106 6 × 106 10 × 106
Number of subjects 5 5 5 5
Sex, female:male ratio 3:2 2:3 1:4 3:2
Age (y) 65.4 (9.5) 68.2 (6.4) 65.8 (7.9) 66.4 (5.9)
Disease duration (y) 5.9 (1.5) 4.7 (3.0) 5.8 (1.5) 5.6 (0.9)
Handedness, right:left ratio 5:0 5:0 4:1 3:2
Race(white, Hispanic, Asian,









MoCA 27 (2.0) 28 (1.7) 24.6 (0.9) 26.6 (1.7)
UPSIT 40-item test 25.8 (7.1) 15.4 (6.7) 22.4 (6.5) 19.4 (6.3)
UPDRS-Ma 32.8 (8.7) 36.2 (18.1) 30.2 (13.7) 36.0 (11.5)
UPDRS-Ta 52.8 (18.9) 48.8 (23.4) 47 (17.2) 53.8 (13.0)
MDS-UPDRS-Ma 35 (11.4) 39.6 (20.9) 34.2 (14.0) 45 (13.1)
MDS-UPDRS-Ta 67.6 (24.0) 57.2 (29.7) 67.8 (19.9) 78.2 (15.4)
H&Ya 1.7 (0.7) 2 (0.7) 2.3 (0.4) 2.4 (0.5)
TUG,a s 17.8 (7.2) 19.7 (5.6) 18.8 (6.6) 15.7 (3.3)
LEDD 711 (403.9) 797.4 (288.5) 438.2 (358.3) 674.6 (203.9)
Levodopa challenge, % improvement 66.2 (14.6) 69.8 (13.1) 64.8 (18.6) 77.2 (7.3)
Data are mean (SD) or n (%).
aPerformed in the conventional OFF state (≥12 hours without PD meds).
Levodopa challenge, percentage of improvement in the UPDRS-M in the ON state versus the OFF state.
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the patient remained asymptomatic, has not received
chemo-reductive therapy, and is under scheduled
monitoring.
Laboratory assessment showed a transient decrease
in lymphocytes in 30% of the patients (n = 6) and a
transient increase in basophils in 20% of the patients
(n = 4). These changes did not last more than 3 months
and were not related to any specific disease process.
Suicidal ideation did not emerge during the study.
There was no relationship between the incidence of
adverse events and dose. No trends emerged between the
dose groups from physical or neurological examinations.
Panel Reactive Antibody
Serum samples were compared with baseline 3, 12,
24, and 52 weeks postinfusion. Of the 20 patients,
17 demonstrated the presence of anti-HLA anti-
bodies, with 14 possessing anti-HLA antibodies with
identical specificities or fewer throughout the study,
with no DSA. Of the 3 samples that contained DSA
postinfusion, only 2 had de novo DSA. One of the
2, with de novo DSA presented with an upper respi-
ratory infection, with the sample containing suspected
DSA being collected during the late stage of infection





n = 5 (100%)
Group B
n = 5 (100%)
Group C
n = 5 (100%)
Group D
n = 5 (100%)
AE relationship
to MSC
Cardiovascular Hypertension 2 (40%) 2 (40%) 0 0 Unlikely related
Phlebitisa 0 0 0 1 (20%) Related
Hematomaa 0 0 1 (20%) 0 Related
Gastrointestinal Nauseab 1 (20%) 2 (40%) 0 0 Possibly related
Neurologic Headachea 0 1 (20%) 0 0 Possibly related
Dyskinesia 1 (20%) 0 2 (40%) 1 (20%) Probably related
Hematology CLL 0 0 1 (20%) 0 Possibly related
Laboratory #Lymphocytesb 3 (60%) 2 (40%) 0 1 (20%) Possibly related
"Basophilsb 1 (20%) 1 (20%) 1 (20%) 1 (20%) Possibly related
Data show n (%) per dose group.
aThere were 3 AEs during the infusion procedure.
bMild and transient. Four patients required management, 1 for hypertension and 3 for exacerbation of dyskinesias.
CLL, chronic lymphocytic leukemia.
FIG. 1. Changes in cytokines, chemokines, and growth factor after allo-hMSC infusion. Mean ± SEM change compared with baseline (BL) values for
TNF-α, CCL22, and BDNF for group C (A–C) and group D (E–G). *P < 0.05.
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with no detectable DSA in subsequent samples. The
final patient with suspected de novo DSA exhibited
diarrhea of unknown origin around the time of sam-
ple collection. DSA was not present in subsequent
samples.
Peripheral Responses
Overall, our data showed downregulation of inflamma-
tory cytokines paired with an increase in BDNF occurring
in the higher-dose groups C and D (Fig. 1). TNF-α, a
proinflammatory cytokine, decreased at 24 and 52 weeks
in group C by 42% and 50%, respectively, and at 3, 12,
and 52 weeks in group D by 26%, 48%, and 54%,
respectively (P < 0.05). CCL22, which displays chemotac-
tic activity for monocytes, dendritic cells, natural killer
cells, and T lymphocytes, decreased at 24 and 52 weeks
in group C by 45% and 50%, respectively, (P < 0.05)
and by 46%, 37%, and 36% at 12, 24, and 52 weeks,
respectivey, in group D (P < 0.05). Last, BDNF, a neuro-
trophic factor that modulates synaptic plasticity and pro-
motes neuronal survival, increased by 50% at 52 weeks
in group D (P < 0.05). There was no significant change in
TNF-α, CCL22, and BDNF for groups A and B (data
shown in Supplemental Table S1). CXCL10, CCL2, and
CCL11 showed no consistent response trend in any of
the 4 groups.
Pseudo-Continuous Arterial Spin
Pseudo-continuous arterial spin showed a significant
main effect of time (P < 0.001) and region (P < 0.001),
but no significant main effect of hemisphere (P = 0.401) or
cohort (P = 0.088). Perfusion increased overall from base-
line to 24 weeks postinfusion in all basal ganglia structures
(mean difference  standard error, 2.980  0.590
mLmin/100 g; Tukey’s t = 5.049, P < 0.001). Post hoc
time-by-region comparisons revealed the most significant
increase in perfusion as a function of time after the allo-
hMSC infusion was in the subthalamic nucleus (STN;
mean difference  standard error, 5.844  1.669
mLmin/100 g; Tukey’s t = 3.501, P = 0.042; Fig. 2).
Rating Scales
All patients sustained motor improvement when
tested in the OFF state (Fig. 3A–D). Except for 1 patient
who developed dyskinesias 3 weeks postinfusion and
required reduction in dopamine, all patients maintained
their baseline dopaminergic regimen for 24 weeks post-
infusion. The highest dose (10 × 106 allo-hMSCs/kg,
group D) had the most significant effect on reducing the
UPDRS total, UPDRS motor, and H&Y scores. At
52 weeks, group D sustained a mean  SD reduction of
14.4  8.6 in UPDRS motor (P < 0.01), 20.8  12.4 in
UPDRS total (P < 0.05), and 0.5  0.3 in H&Y
(P < 0.05) scores. This decrease was also seen in the
patients who developed dyskinesia as an AE. MDS-
UPDRS was measured only at baseline and week
52 postinfusion. The most substantial reduction in
MDS-UPDRS total (mean  SD, 34.8  17.5; P < 0.05)
and MDS-UPDRS motor (mean  SD, 20  9.7;
P < 0.01) scores were also seen in group D. This was
the case for self-reported ADL scores as well, which
were significantly increased in weeks 3, 12, and 24 in
group D (P < 0.01). At 52 weeks, all groups had a clini-
cally significant reduction in their PDQ-39 scores; the
most considerable reduction was 18.8 points in group
D (not statistically significant). There was no significant
change for the TUG, UPSIT, and MoCA scores.
Discussion
To our knowledge, this is the first study to demon-
strate that a single intravenous infusion of allo-hMSCs
FIG. 2. Perfusion changes. (A) Mean ± SEM CBF change in STN by dosage group and time. ***P < 0.001. (B) Sagittal view with atlas ROIs and crosshair
on STN (cyan) with SN (green) located caudally. (C) Voxel-wise analysis confirms cluster of perfusion difference in STN (MNI, −14, −11, −6).
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is safe, well tolerated, and not immunogenic at doses
that range from 1 to 10 × 106 allo-hMSCs/kg in subjects
with mild to moderate PD. Our pilot study recruited a
diverse group of patients who were sequentially enrolled
into 1 of 4 escalated-dose cohorts. All patients received
1 infusion of their assigned dose without any severe
adverse events occurring during the infusion or within
the first 24 hours. Over a 52-week follow-up, the most
common side effects were dyskinesias (20%, n = 4) and
hypertension (20%, n = 4). Three of the dyskinetic
patients required levodopa reduction, suggesting a possi-
ble change in sensitivity to their prior dopamine regi-
men, supported by the resolution of dyskinesias after
levodopa reduction. Future studies will need to monitor
the emergence or exacerbation of dyskinesias post-allo-
hMSC infusions to explain the mechanism underlying
this phenomenon.
In addition, our study used a 5% buminate medium
as part of the allo-hMSC infusion, which can lead to a
transient blood pressure increase for up to 24 hours
because of a rise in oncotic pressure.33 Four patients
developed hypertension between 3 and 24 weeks post-
infusion, which makes it unlikely to be related to the
medium, with 3 of them transient and not requiring any
therapy. One patient developed stage 2 hypertension
6 months postinfusion requiring medical treatment.
During the study there was 1 SAE, defined by our
DSMB as possibly related based on the absence of litera-
ture on allo-hMSCs related to this specific event. One
patient with a 4-year history of lymphocytosis was diag-
nosed with CLL 8 months after the infusion. As a result
of the low disease burden and given that the patient was
asymptomatic, the treating oncologist did not recom-
mend any cytoreductive therapy. The patient remained
asymptomatic at the end of the study and continues to
be monitored. Future studies should carefully monitor
for lymphocytosis, which should be considered an
exclusion criterion.
Undifferentiated MSCs are reported to express no
major histocompatibility complex class II and low levels
FIG. 3. UPDRS and MDS-UPDRS total and motor changes per dose group after allo-hMSC infusion. Depicts rating scales mean ± SEM changes per
group. (A) UPDRS motor score. (B) UPDRS total score. (C) MDS-UPDRS motor score. (D) MDS-UPDRS total score. *P < 0.05, **P < 0.01.
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of major histocompatibility complex class I and
costimulatory molecules. The cellular microenvironment
into which they are transferred can stimulate matura-
tion, leading to a deleterious alloimmune response in
the recipient. In this study, 70% of the population had
preformed anti-HLA antibodies prior to infusion and
either maintained a level of sensitization or had a reduc-
tion throughout the study. Fifteen percent were not sen-
sitized against HLA antigens, at any point, whereas
another 15% demonstrated anti-HLA sensitization with
DSA, which resolved during the course of the study.
Based on these data, a single infusion of mesenchymal
stem cells did not lead to the development of anti-HLA
antibodies. In future studies with repeated doses, DSA
response should be monitored carefully and should be
used as a decisive safety tool for infusion continuation.
Allo-hMSC effects are likely based on immuno-
modulation and neurotrophic support, which potentially
can be achieved through peripheral administration.
Compared with other routes of delivery, the intravenous
route is the less invasive. Multiple studies have proven
that allo-hMSC quality hinges not only on the culture
methods used but also on the donor profile (age, body
mass index, genetic traits, and medical history). Isolated
MSCs from elderly and/or obese donors have decreased
biological activity.34 To date, there have been numerous
studies of the effects of intravenous MSC therapy on
other neurodegenerative diseases, including multiple sys-
tem atrophy,35 progressive supranuclear palsy,36 multi-
ple sclerosis,37 and amyotrophic lateral sclerosis
(ALS),38 all of which revealed safety and indicated some
evidence of efficacy. This knowledge, along with the
lower immunogenicity of MSCs, supported our choice
of using allo-hMSCs from young, healthy donors as a
potentially effective and viable option for PD treatment.
The potential therapeutic benefit of MSC therapy
relies primarily on paracrine actions.39,40 In this study,
multiple peripheral markers were assessed to elucidate
possible mechanisms of action. Our findings suggest a
reduction in serum levels of TNF-α and CCL22, with
an increase in BDNF. There was an anti-inflammatory
effect that appeared to be more robust in the higher
doses of groups C and D and may be related to a
potential mechanism of action. High levels of TNF-α
and CCL2 and low levels of BDNF have been previ-
ously reported in PD patients.41-43
Moreover, high levels of TNF-α correlate with worse
motor scores.44 Previous animal studies have shown
that intravenous MSCs can reduce TNF-α in the sub-
stantia nigra45 and that systemic deficiency of TNF-α is
associated with improvement.46 Similar to our study, in
2 clinical trials using intravenous MSCs, CCL22 was
significantly decreased at 12 months in autism spectrum
disorder47 and at 2 weeks after infusion in an ALS
study.48 We hypothesized that these peripheral changes
could lead to an anti-inflammatory microglial
phenotype, which in turn could enhance neuronal sur-
vival and promote angiogenesis, consistent with the
finding of increased basal ganglia perfusion.
Furthermore, we found no evidence for hemispheric
differences in perfusion. Although the most significant
increase occurred in cohort C, there was no significant
main effect of the overall dose groups. There was an
increase in STN perfusion. The STN plays an essential
role in PD symptomatology, especially in direct–indirect
pathway imbalance. Studies reporting resting cerebral
blood flow (CBF) perfusion, as opposed to resting con-
nectivity of STN, are limited. However, a recent report
of ASL-derived CBF values found no significant differ-
ences between early PD patients and controls, although
there was a trend for increased perfusion in PD that did
not survive multiple-comparison corrections.49 This
may be concordant with increased neuronal activity,
but whether it corresponds to regularization of an irreg-
ular firing pattern is unclear.
The clinical assessments (done in the conventional
OFF state) demonstrated changes in motor and non-
motor symptoms starting 3 weeks postinfusion and per-
sisted to the end of the study. For most patients, rating
scores slowly increased over time after the 12-week
postinfusion. However, both the total and motor sub-
scales of the UPDRS and MDS-UPDRS never returned
to baseline levels, with group D having the most signifi-
cant effect. Motor improvement over the 52 weeks is
not expected in the natural progression of PD50,51 and
supports the need for a phase 2 clinical trial to test the
efficacy of allo-hMSCs as a disease-modifying therapy
in Parkinson’s disease.
Study limitations include the small number of
patients, lack of genetic testing and subtyping as part of
the dose assignment process, and the lack of a placebo
group. Differences in genetic makeup and phenotypes
might impact treatment response and should be consid-
ered in further trials. In addition, 16% of the UPDRS
motor improvement could be attributed to the placebo
effect; however, this effect rarely lasts more than
6 months.52 Last, our current tools for assessing disease
severity may be limited, and reliance on estimates of
disease duration based on time of diagnosis may lack
accuracy because motor symptoms may have started
long before an official diagnosis.
In conclusion, this study demonstrated that a single
infusion of allogeneic MSCs ranging from 1 to 10 × 106
intravenous allo-hMSCs/kg was safe, well tolerated, and
not immunogenic in patients with mild- to moderate-
stage Parkinson’s disease. Based on our secondary out-
comes, our study identified a possible dose that had the
greatest effect on clinical progression. This information
supports moving forward to a phase 2 randomized,
placebo-controlled efficacy trial using allo-hMSCs in a
larger population of well-defined Parkinson’s disease
patients.
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